Zobrazeno 1 - 10
of 56
pro vyhledávání: '"R. Brodows"'
Publikováno v:
Peptides. 30:1771-1774
Exenatide, a synthetic peptide originally isolated from salivary secretions of Heloderma suspectum, like other subcutaneously injected peptides, can cause antibody formation. Despite that antibody formation has been observed in some patients, results
Publikováno v:
Diabetes Technology & Therapeutics. 11:339-344
Conventional methods describing daily glycemic variability (i.e., standard deviation and coefficient of variation) do not express risk. Low and High Blood Glucose Indices (LBGI and HBGI, respectively) and Average Daily Risk Range (ADRR) are parameter
Publikováno v:
Endocrine Journal. 56:415-424
This study assessed the dose-dependent efficacy and safety of exenatide over 12 weeks in Japanese patients with type 2 diabetes suboptimally controlled despite therapeutic doses of sulfonylurea (SU), SU plus biguanide, or SU plus thiazolidinedione. P
Publikováno v:
Diabetes Care. 30:2767-2772
OBJECTIVE— This 16-week study explored the safety of substituting exenatide for insulin in patients with type 2 diabetes using insulin in combination with oral antidiabetes agents. RESEARCH DESIGN AND METHODS— Successful maintenance of glycemic c
Autor:
Andreas Festa, Justin Northrup, Michael E. Trautmann, S. Duran, Don Johns, Dennis Kim, R. Brodows, M. A. Nauck
Publikováno v:
Diabetologia. 50:259-267
The aim of this 52-week, open-label, non-inferiority trial was to compare the safety and efficacy of exenatide (an incretin mimetic) with that of biphasic insulin aspart.Patients on metformin and a sulfonylurea were randomised to exenatide (n = 253;
Publikováno v:
Current Medical Research and Opinion. 24:1395-1397
In this report, we quantify the effects of exenatide and glargine on the relative contributions of fasting and postprandial glucose (PPG) excursion to overall hyperglycemia based on self-monitored blood glucose. After 26 weeks of treatment, insulin g
Publikováno v:
Clinical endocrinology. 80(4)
Objective To determine the effect of chronic daily exenatide treatment on β-cell function in type 2 diabetes (T2DM). Background Glucagon-like peptide receptor agonists, such as exenatide, are commonly used to treat patients with T2DM. Drugs in this
Publikováno v:
American journal of hypertension. 23(3)
BACKGROUND The majority of patients with type 2 diabetes mellitus have blood pressure (BP) exceeding the recommended value of
Publikováno v:
Diabetologie und Stoffwechsel. 4
Publikováno v:
Diabetologie und Stoffwechsel. 4